| Biomarker ID | 1364 |
| PMID | 24682418 |
| Year | 2014 |
| Biomarker | COMT [ SNP: rs16982844: C>A] |
| Biomarker Basis | Mutation Based |
| Biomolecule | Mutation |
| Source | Blood |
| Subjects | Humans |
| Regulation | NA |
| Odds Ratio/Hazard Ratio/Relative Risk | HR: 3.40 (95% CI: 1.63–7.10) |
| Effect on Pathways | Pathways include: Estrogen metabolism, Biogenic amine biosynthesis, Methylation, Neurotransmitter clearance in the synaptic cleft, Tyrosine metabolism |
| Experiment | Biochemical recurrence Vs No Biochemical Recurrence |
| Type of Biomarker | Prognostic |
| Cohort | Cohort of 213 men with advanced prostate cancer were chosen for analysis |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p=0.001 |
| Method Used | MALDI-TOF |
| Clinical | No |
| Remarks | Cox regression models included PSA at diagnosis, Gleason score, pathologic T stage, age at diagnosis, neoadjuvant hormone therapy, smoking status, adjuvant therapy, surgical margin, and nodal invasion status. The major-allele homozygotes served as the reference group with a fixed HR of 1.00. |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on independent patient dataset |
| Technical Name | NA |